96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine,plus Efavirenz,in Antiretroviral-Naive,HIV-1-Infected Adults: Assert Study

Abstract

Background

Abacavir/lamivudine (ABC/3TC) and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) are widely used as first-line antiretroviral therapies. However, there are limited data comparing the safety of these therapies with long-term use. The objective of this study was to assess the long-term safety of these commonly used first-line nucleoside/nucleotide combinations each administered with efavirenz (EFV).

Methods

This open-label, 96-week, randomized study compared the safety (renal, bone and metabolic) and efficacy of ABC/3TC and TDF/FTC plus EFV in HLA-B*5701-negative antiretroviral-naive adults.

Results

A total of 385 subjects were enrolled, and 249 (65%) subjects completed the study. The difference in changes from baseline in estimated glomerular filtration rate (calculated by the Modified Diet in Renal Disease equation) between treatment arms was not significant. There was a significant difference between the arms (P<0.0001) for markers of tubular dysfunction (retinol-binding protein and ß-2 microglobulin) favouring ABC/3TC. Hip bone mineral density decreased from baseline in both arms, with a significantly greater decline with TDF/FTC (ABC/3TC -2.2% and TDF/FTC -3.5%; P<0.001 at week 96). Subjects in the ABC/3TC arm had greater increases from baseline in median total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides. Adverse events were similar between arms. The virological failure rate was low in both arms.

Conclusions

ABC/3TC and TDF/FTC in combination with EFV minimally affected estimated glomerular filtration rate over 96 weeks. TDF/FTC was associated with greater increases in tubular dysfunction and bone turnover marker levels, greater decreases in hip bone mineral density, and smaller increases in serum lipid levels.

References

European AIDS Clinical Society. European AIDS Clinical Society (EACS) Guidelines. Version 6.0 – October 2011. (Accessed 15 May 2012.) Available from http://www.eacsociety.org/Portals/0/files/pdf%20files/EACSGuidelines-v6.0-English.pdf.

Thompson

M.A.

, Aberg

J.A.

, Cahn

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society–USA panel. JAMA 2010; 304: 321–333.

Hetherington

, McGuirk

, Powell

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23: 1603–1614.

Mallal

, Phillips

, Carosi

HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568–579.

D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417–1426.

Kim

, Gupta

S.K.

, Green

Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells. Antivir Ther 2011; 16: 1335–1339.

Ding

, Andraca-Carrera

, Cooper

No association of myocardial infarction with abacavir use: findings of an FDA meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract O-1004.

Cruciani

, Zanichelli

, Serpelloni

Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011; 25: 1993–2004.

Brothers

C.H.

, Hernandez

J.E.

, Cutrell

A.G.

Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51: 20–28.

10.

Gallant

J.E.

, DeJesus

, Arribas

J.R.

Tenofovir DF, emtricitabine, and efavirenz versus zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251–260.

11.

Cassetti

, Madruga

J.V.

, Suleiman

J.M.

The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007; 8: 164–172.

12.

Gallant

J.E.

, Staszewski

, Pozniak

A.L.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191–201.

13.

Arribas

J.R.

, Pozniak

A.L.

, Gallant

J.E.

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47: 74–78.

14.

Viread (tenofovir disoproxil fumarate). Package insert 2012. Gilead Sciences, Inc., Foster City, CA, USA.

15.

Verhelst

, Monge

, Meynard

J.L.

Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 1331–1333.

16.

Karras

, Lafaurie

, Furco

Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070–1073.

17.

Créput

, Gonzalez-Canali

, Hill

Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003; 17: 935–937.

18.

Calza

, Trapani

, Tedeschi

Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients. Scand J Infect Dis 2011; 43: 656–660.

19.

Horberg

, Tang

, Towner

Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010; 53: 62–69.

20.

Duvivier

, Kolta

, Assoumou

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 27: 817–824.

21.

Hansen

A.B.

, Obel

, Nielsen

, Pedersen

, Gerstoft

Bone mineral density changes in protease inhibitor-sparing vs nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 2011; 12: 157–165.

22.

McComsey

G.A.

, Kitch

, Daar

E.S.

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203: 1791–1801.

23.

van Vonderen

M.G.

, Lips

, van Agtmael

M.A.

First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23: 1367–1376.

24.

Bedimo

, Maalouf

N.M.

, Zhang

, Drechsler

, Tebas

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012; 26: 825–831.

25.

Triant

V.A.

, Brown

T.T.

, Lee

, Grinspoon

S.K.

Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large US healthcare system. J Clin Endocrinol Metab 2008; 93: 3499–3504.

26.

Womack

J.A.

, Goulet

J.L.

, Gibert

Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS ONE 2011; 6: e17217.

27.

Post

F.A.

, Moyle

G.J.

, Stellbrink

H.J.

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1– infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55: 49–57.

28.

Stellbrink

H-J

, Orkin

, Arribas

J.R.

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51: 963–972.

29.

Bernard

A.M.

, Vyskocil

A.A.

, Mahieu

, Lauwerys

R.R.

Assessment of urinary retinol-binding protein as an index of proximal tubular injury. Clin Chem 1987; 33: 775–779.

30.

Chitra

, Bakthavatsalam

, Palvannan

Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy. Clin Chim Acta 2011; 412: 1151–1154.

31.

McComsey

, Kitch

, Daar

Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. 17th Conference on Retroviruses and Opportunistic Infections 16–19 February 2010, San Francisco, CA, USA. Abstract 106LB.

32.

Sax

P.E.

, Tierney

, Collier

A.C.

Abacavir–lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361: 2230–2240.

33.

Smith

K.Y.

, Patel

, Fine

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23: 1547–1556.